Sn-Protoporphyrin Use in the Management of Hyperbilirubinemia in Term Newborns With Direct Coombs-Positive ABO Incompatibility
The DOI matches its OpenAlex record.
Abstract
In two separate studies, in which two different treatment regimens of Sn-protoporphyrin were used, a total of 69 control and 53 treated infants were studied to determine whether this potent inhibitor of the enzyme, heme oxygenase, could ameliorate the severity of the hyperbilirubinemia which develops in term babies with direct Coombs-positive ABO incompatibility. The results indicate that Sn-protoporphyrin can, in appropriate doses, moderate the postnatal rate of increase of plasma bilirubin levels and diminish the intensity of hyperbilirubinemia in treated babies. In addition, a decreased use of phototherapy in Sn-protoporphyrin-treated infants was observed. No rebound hyperbilirubinemia was detected during the six- to eight-day period after Sn-protoporphyrin administration. The plasma clearance (t1/2) of Sn-protoporphyrin was much faster in newborns than in adults (approximately 1.6 hours v 3.5 hours, respectively). The incidence of clinical side effects in the 53 Sn-protoporphyrin-treated infants was limited to the development of transient erythema during the use of concurrent phototherapy in two babies. In both infants this reaction subsided completely without sequelae. The use of Sn-protoporphyrin or related synthetic heme analogues to diminish the severity of hyperbilirubinemia in newborn infants merits further study because inhibition of the rate-limiting enzyme in the catabolism of heme to bilirubin may prove to be a useful therapeutic approach in the clinical management of neonatal hyperbilirubinemia, especially in settings in which, for social or economic reasons, other treatment modalities are not available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
“…and Kappas, 1981; Yoshinaga et al., 1982a) was first shown to be therapeutically important when a safe and effective method for transiently blocking bilirubin production in newborns was developed (Kappas et al., 1988, 1995, 2001a,b; Valaes et al., 1998; Martinez et al., 1999; Kappas, 2004).”
Self-citationMetal Complexes as Photo- and Radiosensitizers
Ali, H., & van Lier, J. E. (1999) · Chemical Reviews · doi:10.1021/cr980439y · Cited by 848
Gasotransmitters in cancer: from pathophysiology to experimental therapy
Szabo, C. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.1 · Cited by 717
Zinc Protoporphyrin: A Metabolite with a Mission
Labbé, R. F., Vreman, H. J., & Stevenson, D. K. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.12.2060 · Cited by 270
Cunnington, A. J., de Souza, J. B., Walther, M., & Riley, E. M. (2012) · Nature Medicine · doi:10.1038/nm.2601 · Cited by 231
Metadata
- Authors
- Kappas, A., Drummond, G. S., Manola, T., Petmezaki, S., & Valaes, T.
- Venue
- PEDIATRICS
- Publisher
- American Academy of Pediatrics
- Published
- 1988-04-01
- Volume
- 81
- Issue
- 4
- Pages
- 485-497
- ISSN
- 0031-4005 (ISSN-L)
- OpenAlex
- W1656167931
- Cited by
- 153
- References
- 0
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sn-Protoporphyrin Use in the Management of Hyperbilirubinemia in Term Newborns With Direct Coombs-Positive ABO Incompatibility. https://app.cochat.ai/papers/10.1542/peds.81.4.485
- The paper
- Kappas, A., Drummond, G. S., Manola, T., Petmezaki, S., & Valaes, T. (1988). Sn-Protoporphyrin Use in the Management of Hyperbilirubinemia in Term Newborns With Direct Coombs-Positive ABO Incompatibility. PEDIATRICS. https://doi.org/10.1542/peds.81.4.485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.